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The antiphospholipid antibody syndrome is a systemic, acquired, immune-mediated disorder characterized by episodes of venous,
arterial, or microcirculation thrombosis and/or pregnancy abnormalities, associated with the persistent presence of autoantibodies,
confirmed at least in two occasions 12 weeks apart, directed to molecular complexes consisting of phospholipids and proteins.
Antiphospholipid antibody syndrome should always be considered as a potential diagnosis especially for young patients presenting
with a history of thrombotic events, in particular when they occur without any obvious external trigger or any inherited
thrombophilic mutation (even if 2006 criteria do not exclude antiphospholipid antibody syndrome in patients with other inherited
or acquired prothrombotic conditions), or for women with recurrent pregnancy losses or later fetal deaths. Many other disorders
are able to mimic antiphospholipid antibody syndrome, so a broad range of alternative diagnoses should be investigated and ruled
out during clinical workup.
1. Introduction
Antiphospholipid antibody syndrome (APS) is a systemic,
autoimmune, acquired disorder characterized by venous
and/or arterial thrombosis and/or pregnancy morbidities,
associated with the positivity, confirmed at least in two
occasions 12 weeks apart, of such autoantibodies directed
toward molecular complexes of phospholipids and proteins.
A broad range of different diagnoses should be investigated
and ruled out during diagnostic workup, because many other
disorders are able to mimic APS. This entity should always
be considered especially in young patients with history of
thrombotic events without inherited thrombophilicmutation
or external trigger or in women with recurrent pregnancy
losses or later fetal deaths. According to 2006 Miyakis classi-
fication criteria, the presence of other inherited or acquired
prothrombotic conditions does not exclude APS diagnosis.
On the other hand, the identification of patients with the so-
called APS “noncriteria” is important because these patients
have often an autoimmune disorder that can evolve into a true
APS during followup [1, 2].
In clinical practice, according to these classification crite-
ria, it is possible to identify the following situations.
(a) Patients with usual clinical manifestations of APS asso-
ciated with positivity of antiphospholipid antibodies
(aPL): thrombotic events in typical districts such as
deep vein thrombosis of the lower limbs, pulmonary
embolism, myocardial infarction, and stroke or typi-
cal pregnancy disorders. This is the typical APS.
(b) Patients with unusual clinical presentation of typical
manifestations of APS associated with positivity of aPL:
for example, thrombotic events in atypical districts,
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particularly liver, renal, adrenal, and mesenteric ves-
sels or cerebral venous sinuses with unclear presenta-
tion and difficult diagnosis.
(c) Female patients with incomplete clinical manifestations
of obstetric APS associated with positivity of aPL:
pregnancy disorders not completely fulfillingMiyakis
criteria (e.g., 2 consecutive abortions before the 10th
week of gestation or 3 or more nonconsecutive abor-
tions before the 10th week).
(d) Patients with noncriteria clinical manifestations of
APS associated with positivity of aPL: for example,
nonthrombotic pulmonary or cardiac involvement,
ocular, neurological, osteoarticular, and hematologi-
cal manifestations.
In (a) situation, diagnosis is usually simple. However, special
attention deserves the exclusion of certain conditions, such as
microangiopathic syndromes or systemic lupus erythemato-
sus (SLE).
In (b) condition, the absence of nonspecific clinical
manifestations (e.g., an acute abdominal pain due to visceral
thrombosis) could make APS diagnosis more complex.
In (c) and (d) cases the patient who presents noncriterial,
but suggestive, clinical features deserves a careful followup
to detect early “clinical criteria” and to establish the best
treatment.
Particular attention must be paid to those forms charac-
terized by typical thrombotic events or pregnancy disorders
in the absence of other causes, without aPL positivity (the
so-called “seronegative APS”); probably, at the present time
laboratory tests are inadequate to detect all APS patients since
recently the existence of “noncriterial” potentially diagnostic
antibodies has been proposed [3].
For diagnostic algorithm, see Figure 1.
2. Definite APS with Usual
Clinical Manifestations
Thrombotic events in APS can involve both arterial and
venous vessels of any size and district, sometimes requiring
a broad number of medical conditions to be ruled out (see
Table 1).
2.1. Microangiopathic Syndromes. Thrombotic microangio-
pathic syndromes include thrombotic thrombocytopenic
purpura (TTP), hemolytic uremic syndrome (HUS), and
hemolysis, elevated liver enzymes, and low platelets (HELLP)
syndrome; these disorders are characterized by platelet
consumption, intravascular hemolysis with schistocytes due
to red cell fragmentation, and clinical/laboratory findings
of organ dysfunction; histologically they are all marked
by small vessel occlusion with hyaline thrombi and fibrin
deposition. Interestingly, aPL have not been rarely detected
in these conditions and on the other hand APS does not
infrequently show some degree of microangiopathic involve-
ment, especially in its catastrophic form; indeed, catastrophic
antiphospholipid syndrome (CAPS) is considered the most
devastatingmanifestation of APS, fatal up to 50% of cases and
Table 1: Main differential diagnosis of APS with usual clinical man-
ifestations.
(i) Microangiopathic syndromes (TTP/HUS, HELLP)∗
(ii) Heparin induced thrombocytopenia (HIT)
(iii) Disseminated intravascular coagulation (DIC)
(iv) Systemic lupus erythematosus
(v) Behc¸et’s syndrome
∗TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic
syndrome; HELLP: hemolysis, elevated liver enzymes, and low platelets.
characterized by multiple organ dysfunction developing in a
few days, due to intravascular microthrombosis. For all these
conditions the term MAPS (microangiopathic antiphospho-
lipid syndrome) has been proposed [4, 5].
2.1.1. Thrombotic Thrombocytopenic Purpura. Moschowitz
syndrome, the eponym of TTP, is mainly characterized
by fever, microangiopathic hemolytic anemia, thrombocy-
topenia, and severe neurological involvement, while renal
involvement is quite rare; diagnostic markers are considered
the presence of high levels of circulating ultralarge von
Willebrand factor (ULVWF) multimers and schistocytes.
Of note, in acquired autoimmune form, the presence of
antibodies against the metalloproteinase ADAMTS13 could
be useful for differential diagnosis; on the other hand aPL
have been occasionally reported in TTP patients [6].
Interestingly in TTP 90% of deaths are from myocardial
infarction (due to platelet thrombi in the coronary circula-
tion). Myocardial infarction is also a frequent manifestation
of arterial thrombosis in APS.
In clinical practice APS rarely presents a severe thrombo-
cytopenia such as in TTP.
2.1.2. Hemolytic Uremic Syndrome. HUS is clinically charac-
terized by microvascular thrombosis with consequent tissue
ischemia and necrosis with renal failure, thrombocytopenia,
and microangiopathic anemia. There are two distinct forms:
(a) diarrhea-associated HUS, typically correlated with Shiga-
like toxin-producing bacteria (STEC-HUS), and (b) atypical
HUS (diarrhea nonassociated) which represents a frequent
form of HUS in adults [7, 8].
Clinical issues for differential diagnosis are mainly rep-
resented by the rapid onset of renal involvement and the
presence of microangiopathic anemia with thrombocytope-
nia associated with episodes of diarrhea. aPL are usually not
found in this condition.
2.1.3. Hemolysis, Elevated Liver Enzymes, and Low Platelets.
HELLP syndrome is more common in multiparous women
between the 27th and the 37th week of gestation; clinically, it
is characterized by gastrointestinal involvement (abdominal
pain with nausea and vomiting), generalized edema, signs of
hemolysis, elevated liver enzymes, severe thrombocytopenia,
and signs of renal failure. Of note severe hypertension is not
usually found in HELLP syndrome, helping to distinguish it
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Figure 1: Clinical suspicion for definite and noncriterial APS.
from preeclampsia (even if they can coexist in about 70–80%
of cases) [9].
Differential diagnosis is complicated by the evidence that
also APS patients can experience HELLP syndrome during
pregnancy [10].
2.2. Heparin Induced Thrombocytopenia. Another clinical
condition, potentially very severe, characterized by throm-
bocytopenia and multiple thrombotic occlusions of small
vessels, is heparin induced thrombocytopenia (HIT), which
should be suspected early during heparin treatment [11].
Two major forms have been described:
(a) type I HIT, with favorable prognosis, occurs in
approximately 10% of patients undergoing both low
molecular weight heparin (LMWH) and unfraction-
ated heparin (UH) therapy. It occurs very early
usually within the first four/five days of therapy
(thought to be caused by direct platelet activation
from heparin) and resolves without treatment and
without any complication since it is not associated
with thrombotic events;
(b) type II HIT, which involved 1–5% of patients under-
going heparin therapy (more frequently using unfrac-
tionated heparin compared to LMWH), is associated
with microthrombosis involving multiple districts
affecting both the arterial and the venous vessels
(in such cases the risk of mortality is estimated
to be 20–30%). Diagnostic marker is considered a
platelet count which falls by about 50% compared
to baseline after 5–15 days from the beginning of
heparin therapy. Of note in type II HIT the pro-
duction of specific antiplatelet antibodies (i) may
not be associated with thrombocytopenia or (ii) may
be associated with thrombocytopenia but not with
thrombotic complications or (iii) may be associated
with both thrombocytopenia and thrombosis.
The pathogenesis of HIT has been recently better defined:
during the early phase heparin binds to platelet factor 4 (PF4),
generating a complex (heparin-PF4) toward which IgG anti-
bodies are produced and this complex is also able to activate
platelets via Fc𝛾RIIa receptor, causing microthrombosis and
thrombocytopenia.
The detection of antibodies to heparin-PF4 complex for
HIT laboratory diagnosis can be performed using either a
serotonin release assay (SRA), with low sensitivity and high
specificity for HIT, or an ELISA test, more sensitive but less
specific for HIT. Of note the diagnosis not only is based on
these tests but also is currently based on probability according
to a compatible clinical scenario [12].
HIT treatment requires immediate discontinuation of
heparin and the beginning of an alternative anticoagulation
strategy with direct thrombin inhibitor, heparinoids or pen-
tasaccharides.
Both APS and HIT can present thrombocytopenia (usu-
ally more severe in HIT) and thrombosis, but anamnestic
clues (i.e., previous heparin exposure and the correlationwith
thrombocytopenia onset) and the absence of aPL could help
in diagnostic workup.
2.3. Disseminated Intravascular Coagulation. Disseminated
intravascular coagulation (DIC) is characterized by mic-
rovascular thrombosis, possibly leading to consumptive
coagulopathy and bleeding, which can in turn lead to
multiple organ failure; it is secondary to surgery, chronic
inflammatory diseases or malignancies, and sepsis. Labo-
ratory markers of DIC are thrombocytopenia, prolonged
clotting times, increased levels of fibrin degradation products,
and reduced plasma fibrinogen.
Differential diagnosis withAPS could be difficult, because
DIC is able to both mimic and complicate APS, especially in
its catastrophic form (CAPS), which is characterized by dis-
seminated intravascular thrombosis resulting in multiorgan
failure; an aid in clinical practice could be the evidence that
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Figure 2: Clinical and laboratory findings in microangiopathic syndromes, DIC and HIT.
more frequently DIC presents thrombotic and hemorrhagic
complications at the same time [13].
However, one should keep in mind that the main clinical
presentation in DIC is hemorrhage and sepsis is the most
common cause.
For clinical and laboratory findings in microangiopathic
syndromes, DIC and HIT, see Figure 2.
2.4. Systemic Lupus Erythematosus. In Miyakis criteria the
term “secondary APS” is considered inappropriate because
SLE and APS may represent a different spectrum of the same
disease, underlying the strong relation existing between these
conditions [1].
Indeed not only SLE patients could present aPL positivity
associated with vascular involvement or obstetrical disease,
but also APS patients could present some SLE features, such
as autoimmune hemolytic anemia and mild reduction in
complement, anti-nuclear antibodies (ANA); interestingly,
these patients can be considered as APS patients who likely
will evolve into SLE over time.
Renal involvement in APS patients is not infrequent;
markers to distinguish SLE renal involvement fromAPS ones
are a significant titer of circulating ANA, the presence of
other autoantibody specificities such as anti-native DNA,
anti-Sm or anti-C1q, complement consumption, and specific
histological findings from renal biopsy.
Given that both APS and SLE could present similar
neurological symptoms and MR findings, another clinical
challenge is the differential diagnosis with Neuro-SLE [14].
This discrimination is fundamental in clinical practice since
in the case of APS anticoagulants are the main treatment,
while Neuro-SLE requires the use of pulse high dose steroids
associatedwith immunosuppressive drugs [15].The detection
of a significant titer of specific circulating autoantibodies such
as anti-ribosomal P, low complement levels, or other organs
involvement should be more suggestive of SLE.
2.5. Behc¸et’s Syndrome. Behc¸et syndrome (BS) is a systemic
vasculitis characterized by mucocutaneous, ocular, and neu-
rological involvement. Moreover a significant proportion
of Behc¸et patients results very prone to recurrent vascular
thrombosis, which could represent the main clinical man-
ifestation of the disease, so complicating the differential
diagnosis withAPS; due to its primary inflammatory vascular
origin, the thrombotic events in BS need corticosteroid or
immunosuppressive therapy rather than anticoagulation [16].
Noteworthily the inappropriate use of anticoagulants in
BS could be harmful if used in patients with clinically occult
pulmonary artery aneurisms, since the risk of rupture is very
high in this setting [17].
Of note as APS also BS can be responsible for cerebral
venous sinus thrombosis and parenchymal lesions [18, 19].
Neuro-Behc¸et (NB) brain inflammatory lesions are typically
located deeply at the level of basal ganglia and brainstem,
while APS usually involves the subcortical and periventric-
ular white matter areas; this differential diagnosis is decisive
because, even in this case, NB requires immunosuppressive
treatment [20].
In summary aPL can be found in Behc¸et patients with
doubtful clinical significance [21]. However, recurrent bipolar
aphthosis and ocular involvement, when present, are highly
specific for BS.
3. Definite APS with Unusual
Clinical Manifestations
Thrombotic manifestations of APS may have an unclear
clinical presentation when they occur in atypical sites.
3.1. Neurological Involvement. Cerebral ischemic events are
the main neurological manifestations of APS, while cerebral
venous thrombosis is considered rare events but must always
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be considered in diagnostic workup because signs and symp-
toms may be unclear and diagnosis may be difficult without
a specific approach [22].
3.2. Renal Involvement. Kidney manifestations are less fre-
quent and less recognized in APS than in SLE patients and
mainly differ for their primary vascular involvement with
only secondary glomerular damage [23, 24]. Indeed the main
events are renal vein thrombosis, characterized by sudden
clinical presentation as untreatable hypertension, secondary
nephrotic syndrome, and renal infarction. Another manifes-
tation is kidney microangiopathy affecting afferent arterioles
and clinically characterized by hypertension and laboratory
signs of renal failure. Histological alterations are marked
by thrombotic microangiopathy with fibrin deposition and
microthrombi causing secondary glomerular dysfunction,
interstitial fibrosis, and tubular atrophy; the presence of
aPL and typical histopathologic features, involving both
arterioles and glomerular capillaries, are the hallmarks of
APS associated nephropathy [25, 26]. In clinical practice,
for patients with SLE and aPL positivity, a biopsy procedure
is necessary to differentiate inflammatory damage from
thrombotic damage, since the therapeutic approaches are
quite different; moreover, renal damage due to APS on kidney
histology seriously affects lupus nephritis outcome and long-
term anticoagulant therapy has been recommended for such
patients [27].
3.3. Gastrointestinal Involvement. Thromboses of arterial or
venous districts such as sovraepatic (Budd-Chiari syndrome),
portal, mesenteric andmore rarely of the splenic veins are the
main events of gastrointestinal involvement in APS patients;
differential diagnosis in these cases should be myeloprolifer-
ative disorders and in such cases the determination of JAK2
is crucial [28]. Henoch-Scho¨nlein purpura and polyarteritis
nodosa should be considered in differential diagnosis with
APS with prevalent involvement of gastrointestinal tract,
even though, differently from vasculitides, APS usually is
not associated with increased serum levels of inflammatory
markers. Noteworthily gastrointestinal events are more fre-
quent in CAPS which should be always suspected in patients
who present with rapid and severe multiorgan ischemic
dysfunction [29].
3.4. Endocrinological Involvement. Adrenal insufficiency sec-
ondary to acute vascular infarction is the main, even though
rare, manifestation of APS but diagnosis can be hard [30].
4. Incomplete Pregnancy Manifestations
Pregnancy disorders not completely fulfillingMiyakis criteria
(i.e., 2 consecutive abortions or 3 or more nonconsecutive
abortions before the 10th week of gestation) may raise the
suspicion of APS; however, many other clinical conditions
must be excluded, such as anatomic dysfunction, endocrine
disorders, coagulopathies, or other autoimmune diseases, for
example, SLE, autoimmune thyroiditis, or celiac disease [31].
5. Noncriterial Clinical Clues
Differential diagnosis results more complex for such noncri-
terial clinical clues whose presence does not allow, according
to Miyakis consensus, a diagnosis of definite APS, even
though this clinical presentation strongly suggests the suspi-
cion of APS or the potential evolution over time towards it.
These patients represent a significant proportion of subjects
to be prospectively evaluated in order to detect earlymanifes-
tations of definite disease.
5.1. Neurological Involvement. Brain MR imaging could be
similar for morphology and location in multiple sclerosis
(MS) and APS with SNC involvement [32]; moreover, ANA
and aPL (especially anti-𝛽2GPI of IgM isotype) could be
present also in MS patients, making in some cases the differ-
ential diagnosis between the two conditions more difficult.
Usually the diagnosis of demyelinating disease is supported
by the presence of lesions involving the periventricular and
corpus callosumareas and the detection of oligoclonal bands
from cephalospinal fluid [33, 34].
Devic’s syndrome, nowadays known as neuromyelitis
optica (NMO), is considered a distinct disorder from MS,
since it recognizes a different inflammatory pathway and
the presence of aquaporin-4 (anti-NMO) antibodies is con-
sidered the main pathogenetic player and a diagnostic
biomarker. In particular testing patients for anti-NMO anti-
bodies is strongly recommended in subjects who present
severe optic neuritis (usuallymore serious than inMS) and/or
with transverse myelitis longitudinally extended, defined
as a spinal inflammatory lesion involving at least three
consecutive vertebrae [35].
NMO can coexist with SLE and APS in the same patient;
diagnoseNMO typical ocular/spinal pattern investigating the
presence of anti-NMO is crucial, since this lead to the correct
treatment with plasmapheresis or other immunosuppressive
treatment [36].
5.2. Cutaneous Involvement. Livedo, acrocyanosis, and
peripheral ulcers represent the most likely cutaneous
manifestations of APS [37, 38].
Livedo of the limbs, the most characteristic cutaneous
manifestation in APS patients, is histologically marked by
partial or complete lumen occlusion of small or medium
caliber arteries of dermo-hypodermis without perivascular
inflammatory infiltrates. Of note only livedo racemosa (irreg-
ular and interrupted borders) is associated with pathological
conditions such as APS, while livedo reticularis (circular and
continuous borders) is considered a benign condition and is
more commonly encountered during clinical practice [39].
A debate exists about differential diagnosis between APS
and Sneddon’s syndrome, since both are characterized by
the presence of cerebrovascular accidents and cutaneous
manifestations such as peripheral ulcers and livedo. Markers
for differential diagnosis could be considered in Sneddon’s
syndrome patients as follows: the presence of high blood
pressure, the extent of livedo (generally very pronounced),
and the absence of circulating aPL. Skin biopsy can show
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in selected circumstances histological findings of endothelial
cell proliferation and occlusion of the small cutaneous vessels,
more related to Sneddon’s syndrome [40].
5.3. Nonthrombotic Cardiac and Pulmonary Involvement.
Heart valves dysfunctions, generally of themitral valve, rang-
ing from mild valve thickening to the typical nonbacterial
thrombotic lesions (Libman-Sacks endocarditis) have been
demonstrated by echocardiographic studies [41]. Cardiomy-
opathy in APS patients is of a quite rare occurrence and
a convincing pathogenetic relationship with circulating aPL
has not been clearly demonstrated [42].
The main pulmonary nonthrombotic manifestations in
APS patients are considered as follows: intra-alveolar hem-
orrhage, acute respiratory distress syndrome (ARDS), and
fibrosing alveolitis [43, 44].
Of note, aPL are often associated with chronic throm-
boembolic pulmonary hypertension [45].
5.4. Ocular Involvement. Amaurosis fugax is the most fre-
quent manifestation, generally without pathological fundo-
scopic findings, and it may represent, rather than an ocular
dysfunction, a warning bell of cerebrovascular disease (i.e.,
transient ischemic attack). On the other hand severe ocular
events which may occur in APS patients are artery or
vein thrombosis, retinal vascular occlusive retinopathy, and
ischemic optic neuropathy, althoughnone of them is included
inMiyakis criteria. Of note, other immunological conditions,
such as giant cell arteritis (GCA), are able to induce ischemic
optic neuropathy with rapidly progressive and severe visual
impairment, but usually in APS inflammatory markers are
normal. APS must be considered in differential diagnosis
especially in young patients presenting with ocular vasooc-
clusive disease without any traditional thrombophilic risk
factors [46, 47].
5.5. Hematological Involvement. Thrombocytopenia, previ-
ously included in classification criteria, is nowadays consid-
ered a noncriterial APSmanifestation and is found in approx-
imately 30–40% of APS patients, justifying aPL screening in
every patient with idiopathic thrombocytopenia. Noteworthy
is that APS-associated thrombocytopenia is generally less
severe than SLE ones and rarely requires aggressive treatment
[48]. In the differential diagnostic workup of APS-related
thrombocytopenia one should always exclude, in addition
to SLE, pseudothrombocytopenia, TTP, DIC, and HIT and,
when hemolytic anemia is present, Evans syndrome, a hema-
tological condition reported to be associated with APS [49].
5.6. Musculoskeletal Involvement. Articular symptoms are
rare APS manifestations and, if present, could always raise
the suspicion of an associated connective tissue disease.
Moreover, especially in CAPS patients, aseptic bone necrosis,
in particular of the femoral head, could be considered [50].
The pathogenesis of aseptic osteonecrosis is not yet def-
initely understood; however, it is believed that microthrom-
bosis or vasculopathy is involved [51].
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